Nuzenio

Marketbeat Keros Therapeutics

Marketbeat Keros Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 7 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeatMarketBeat · Mon, 10 Aug 2026 06:27:32 GMTKeros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 06:05:44 GMTRenaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeatMarketBeat · Fri, 07 Aug 2026 17:49:25 GMTFY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeatMarketBeat · Thu, 06 Aug 2026 12:14:05 GMTKeros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - MarketBeatMarketBeat · Tue, 04 Aug 2026 12:18:37 GMTKeros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeatMarketBeat · Mon, 03 Aug 2026 21:38:53 GMTKeros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research - MarketBeatMarketBeat · Fri, 31 Jul 2026 11:09:08 GMT

Timeline

Mon, 10 Aug 2026 06:27:32 GMTKeros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Sat, 08 Aug 2026 06:05:44 GMTKeros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeat
Fri, 07 Aug 2026 17:49:25 GMTRenaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Thu, 06 Aug 2026 12:14:05 GMTFY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeat
Tue, 04 Aug 2026 12:18:37 GMTKeros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - MarketBeat
Mon, 03 Aug 2026 21:38:53 GMTKeros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Marketbeat Keros Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.